Your browser is no longer supported. Please, upgrade your browser.
GWPH GW Pharmaceuticals plc daily Stock Chart
GW Pharmaceuticals plc
Index- P/E- EPS (ttm)-1.79 Insider Own1.12% Shs Outstand31.29M Perf Week-0.49%
Market Cap3.02B Forward P/E49.15 EPS next Y1.93 Insider Trans-69.33% Shs Float30.83M Perf Month-3.55%
Income-55.50M PEG- EPS next Q-0.84 Inst Own88.80% Short Float16.07% Perf Quarter-26.21%
Sales442.00M P/S6.84 EPS this Y97.60% Inst Trans8.03% Short Ratio13.05 Perf Half Y-10.25%
Book/sh22.91 P/B4.15 EPS next Y192.30% ROA-6.40% Target Price- Perf Year-26.73%
Cash/sh15.01 P/C6.33 EPS next 5Y- ROE-7.70% 52W Range67.98 - 141.98 Perf YTD-9.14%
Dividend- P/FCF- EPS past 5Y19.00% ROI-15.90% 52W High-33.09% Beta1.93
Dividend %- Quick Ratio5.00 Sales past 5Y59.60% Gross Margin92.10% 52W Low39.75% ATR3.00
Employees901 Current Ratio5.80 Sales Q/Q68.50% Oper. Margin-12.20% RSI (14)41.10 Volatility2.83% 3.03%
OptionableYes Debt/Eq0.02 EPS Q/Q-111.10% Profit Margin-12.60% Rel Volume0.68 Prev Close97.04
ShortableYes LT Debt/Eq0.02 EarningsNov 03 AMC Payout- Avg Volume379.71K Price95.00
Recom1.80 SMA20-1.58% SMA50-5.88% SMA200-14.02% Volume259,903 Change-2.10%
Aug-25-20Initiated Raymond James Mkt Perform
Aug-07-20Reiterated Needham Buy $190 → $180
Jul-15-20Downgrade Stifel Buy → Hold $150 → $140
Jun-30-20Reiterated Evercore ISI Outperform $250 → $275
Jun-01-20Resumed Oppenheimer Outperform $173 → $166
Apr-08-20Initiated Northland Capital Outperform $128
Mar-06-20Initiated Citigroup Buy $192
Oct-30-19Initiated H.C. Wainwright Buy $170
Oct-21-19Initiated Needham Buy $200
May-07-19Upgrade Oppenheimer Perform → Outperform
May-07-19Reiterated Guggenheim Buy $186 → $222
May-07-19Reiterated Cantor Fitzgerald Overweight $196 → $229
Mar-18-19Reiterated Cantor Fitzgerald Overweight $193 → $196
Jan-02-19Initiated JP Morgan Overweight $134
Nov-05-18Resumed Piper Jaffray Overweight
Sep-28-18Reiterated BofA/Merrill Buy $181 → $197
Sep-07-18Resumed Morgan Stanley Overweight
Aug-15-18Initiated Stifel Buy $181
Aug-08-18Reiterated Cantor Fitzgerald Overweight $235 → $211
Apr-19-18Reiterated Cantor Fitzgerald Overweight $192 → $205
Oct-22-20 10:34AM  
Oct-21-20 08:00AM  
Oct-19-20 10:39AM  
Oct-16-20 11:02AM  
Oct-15-20 02:45PM  
Oct-12-20 09:50AM  
Oct-10-20 10:45AM  
Sep-30-20 03:26PM  
Sep-23-20 08:05AM  
Sep-15-20 07:52AM  
Sep-10-20 04:00PM  
Sep-03-20 06:30AM  
Sep-02-20 01:24PM  
Sep-01-20 07:00AM  
Aug-29-20 06:41AM  
Aug-26-20 12:38PM  
Aug-24-20 07:21AM  
Aug-16-20 10:47AM  
Aug-07-20 11:24AM  
Aug-06-20 04:44PM  
Aug-03-20 03:45PM  
Aug-02-20 09:34AM  
Jul-30-20 11:53AM  
Jul-26-20 09:54AM  
Jul-25-20 06:56AM  
Jul-23-20 07:00AM  
Jul-21-20 03:09PM  
Jul-17-20 04:21PM  
Jul-15-20 06:51PM  
Jul-14-20 08:08AM  
Jul-13-20 07:21AM  
Jul-12-20 09:34AM  
Jul-11-20 07:48AM  
Jul-09-20 06:49AM  
Jul-07-20 07:21AM  
Jun-30-20 08:08AM  
Jun-25-20 11:26AM  
Jun-24-20 01:00PM  
Jun-23-20 07:01PM  
Jun-18-20 03:48PM  
Jun-16-20 10:31AM  
Jun-10-20 06:19AM  
Jun-05-20 04:24PM  
Jun-04-20 04:00PM  
Jun-02-20 07:00AM  
May-28-20 02:55PM  
May-24-20 12:25PM  
May-22-20 10:26AM  
May-21-20 02:59PM  
May-13-20 06:19AM  
May-12-20 08:06AM  
May-11-20 06:23PM  
May-07-20 11:17AM  
May-06-20 06:28AM  
May-01-20 07:00AM  
Apr-28-20 10:33AM  
Apr-27-20 08:09AM  
Apr-21-20 02:04PM  
Apr-07-20 11:11AM  
Apr-06-20 09:00AM  
Apr-01-20 12:20PM  
Mar-31-20 07:00AM  
Mar-24-20 04:20PM  
Mar-20-20 07:05AM  
Mar-13-20 07:00AM  
Mar-06-20 03:24PM  
Mar-02-20 01:23PM  
Feb-26-20 04:20PM  
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Snyder Douglas B.Chief Legal OfficerSep 30Sale8.1314,400117,07226,904Oct 02 04:40 PM
Snyder Douglas B.Chief Legal OfficerAug 11Sale9.4024,000225,60041,304Aug 12 08:06 PM
Snyder Douglas B.Chief Legal OfficerAug 10Option Exercise0.00131,544171122,364Aug 12 08:06 PM
Knappertz VolkerChief Medical OfficerAug 04Sale11.116,00066,66047,940Aug 06 08:01 PM
Knappertz VolkerChief Medical OfficerJul 20Sale11.426,00068,52053,940Jul 22 08:00 PM
Snyder Douglas B.Chief Legal OfficerJul 06Sale10.509,804102,9420Jul 08 08:00 PM
Knappertz VolkerChief Medical OfficerJun 17Sale10.3518,000186,30059,940Jun 19 08:02 PM
Gover Justin D.Chief Executive OfficerJun 15Option Exercise0.004,1645458,129Jun 17 08:00 PM
GUY GEOFFREY W DRExecutive ChairmanMay 29Sale10.25720,0007,376,4005,501,521Jun 02 08:00 PM
Cline Darren SU.S. Chief Commercial OfficerMay 28Option Exercise0.007,35697,356May 29 08:00 PM
Knappertz VolkerChief Medical OfficerMay 18Option Exercise0.00133,620160139,092May 20 08:02 PM
Giacobello Scott M.Chief Financial OfficerMay 18Option Exercise0.00116,604140140,742May 20 08:01 PM
Giacobello Scott M.Chief Financial OfficerMar 13Buy6.807,20048,96088,224Mar 17 06:07 PM
GUY GEOFFREY W DRExecutive ChairmanMar 13Sale6.63600,0003,978,0006,221,521Mar 17 06:05 PM
Gover Justin D.Chief Executive OfficerMar 02Option Exercise0.0047,84462599,369Mar 04 06:01 PM
Snyder Douglas B.Chief Legal OfficerMar 02Sale8.322,56821,36667,296Mar 04 06:03 PM
MACKEY CATHERINE JDirectorMar 02Sale8.351,35611,32316,392Mar 04 06:04 PM
Brown CabotDirectorMar 02Sale8.243,14425,90717,088Mar 04 06:03 PM
Gover Justin D.Chief Executive OfficerMar 02Sale8.3332,856273,789566,513Mar 04 06:01 PM
Secor AliciaDirectorMar 02Sale8.341,29610,80916,440Mar 04 06:02 PM
Giacobello Scott M.Chief Financial OfficerMar 02Sale8.342,22018,51581,024Mar 04 06:00 PM
Knappertz VolkerChief Medical OfficerMar 02Sale8.323,42028,45479,392Mar 04 06:01 PM
Snyder Douglas B.Chief Legal OfficerFeb 26Sale9.173,87635,55069,864Feb 28 06:06 PM
Gover Justin D.Chief Executive OfficerFeb 26Sale9.0512,000108,558551,525Feb 28 06:02 PM
Knappertz VolkerChief Medical OfficerFeb 26Sale9.183,01227,63682,812Feb 28 06:02 PM
Giacobello Scott M.Chief Financial OfficerFeb 26Sale9.173,85235,32383,244Feb 28 06:01 PM
Gover Justin D.Chief Executive OfficerFeb 03Option Exercise0.00202,224263765,749Feb 05 05:00 PM
Gover Justin D.Chief Executive OfficerFeb 03Sale9.62202,2241,944,678563,525Feb 05 05:00 PM
GUY GEOFFREY W DRExecutive ChairmanJan 15Sale9.44900,0008,493,0006,821,521Jan 17 05:00 PM
MACKEY CATHERINE JDirectorJan 03Sale8.541,53613,11717,748Jan 07 05:00 PM
Secor AliciaDirectorJan 03Sale8.531,53613,10217,736Jan 07 05:01 PM
Brown CabotDirectorJan 03Sale8.583,57630,68220,232Jan 07 05:01 PM
Gover Justin D.Chief Executive OfficerDec 17Option Exercise0.0010,66814568,865Dec 19 05:02 PM
Gover Justin D.Chief Executive OfficerDec 17Sale9.175,34048,968563,525Dec 19 05:02 PM
GUY GEOFFREY W DRExecutive ChairmanNov 11Sale9.33420,0003,918,6007,721,521Nov 13 05:00 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.